Cytomegalovirus antibody and vascular pathology in renal transplant recipients

Patricia Price\textsuperscript{1,2,3}, Silvia Lee\textsuperscript{1,2,4}, Jacquita Affandi\textsuperscript{1,2}, Richard Parsons\textsuperscript{5}, Louise H. Naylor\textsuperscript{6}, Gerald F. Watts\textsuperscript{3}, Ashley Irish\textsuperscript{3,7}

\textsuperscript{1} School of Biomedical Science, Curtin University, Bentley, Australia
\textsuperscript{2} Curtin Health Innovation Research Institute, Curtin University, Bentley, Australia
\textsuperscript{3} School of Medicine & Pharmacology, University of Western Australia, Nedlands, Australia
\textsuperscript{4} Department of Microbiology, Royal Perth Hospital, Perth, Australia
\textsuperscript{5} School of Pharmacy, Curtin University, Bentley, Australia
\textsuperscript{6} Sport Science, Exercise and Health, University of Western Australia, Nedlands, Australia
\textsuperscript{7} Renal Unit, Fiona Stanley hospital, Murdoch, Australia

\textbf{Corresponding author:}
A/Professor Patricia Price
School of Biomedical Science,
Curtin University of Technology,
Bentley
Australia
Tel: +61 8 9266 9716
Email: patricia.price@curtin.edu.au

\textbf{Key words:}
cytomegalovirus, cardiovascular disease, renal transplantation, aging
ABSTRACT

Cytomegalovirus (CMV) has been linked with vascular pathology and is a common complication of renal transplantation. We addressed whether CMV seropositivity influences vascular pathology several years after transplant. Levels of CMV antibody increased with age, were higher in transplant recipients than healthy controls (p<0.001) and correlated with vascular endothelial function measured by flow mediated-dilation of the brachial artery (FMD). However the optimal general linear model predicting FMD included CMV seropositivity as a marginal effect (p=0.068), with age (p=0.013), gender (p<0.0001) and transplantation (p<0.0001). Other measures of the burden of CMV are being tested as CMV prophylaxis is feasible.

98 WORDS
INTRODUCTION

Most people carry cytomegalovirus (CMV) as a lifelong latent infection, with periodic reactivations triggered by inflammation or stress. CMV is also a common infectious complication of renal transplantation (1). Before prophylaxis was available, one in three renal transplant recipients (RTR) experienced pathologies associated with CMV. For example; 12 of 141 RTR in one study, died with disseminated CMV infection (2). In Australia, it is common practice to administer valganciclovir as prophylaxis for 12-26 weeks after transplantation, based on donor and recipient CMV seropositivity and clinical risk. Under a similar regimen, CMV replication was detected in 33% of previously seropositive RTR and 21% of those who were seronegative at transplantation (3). However the long-term use of valganciclovir after this initial prophylactic period is not standard as there are uncertain benefits and cost. However CMV reactivations are implicated in deterioration in renal function (4), new onset type II diabetes (5) and vascular pathologies. Cardiovascular disease after renal transplantation is a common long-term complication of successful renal transplantation and is more frequent in CMV-positive patients (6,7). Periodic CMV prophylaxis of selected patients stable on anti-rejection therapy is feasible and has the potential to reduce these adverse outcomes.

Several studies associate the presence of CMV-DNA in tissues removed during surgery for abdominal aortic aneurysm with expression of inflammatory mediators (eg: 8). Higher CMV antibody titres are linked with increased blood pressure in young men (9) and coronary artery disease requiring surgery (10). Here we assess whether levels of CMV antibodies or a simple dichotomy of seropositive versus negative independently predict large vessel health assessed by carotid intima media thickness (cIMT) and flow mediated dilatation (FMD) of the brachial artery. cIMT is an independent predictor of clinical cardiovascular events, including myocardial infarction and stroke (11). Brachial arterial FMD is assessed by high-resolution ultrasound after blood flow is occluded for a few minutes. The measurement reflects endothelium-dependent vasodilator function. It is validated as a surrogate of endothelial function of the coronary circulation, and associates with prevalent and incident cardiovascular disease (12).
METHODS

Patients and controls
Renal transplant recipients (RTR; n=82) were recruited from the renal clinics at Royal Perth Hospital (RPH), Western Australia. Inclusion criteria were clinically stable >2 years after transplantation, no CMV disease or reactivation within 6 months of blood collection and no antiviral treatment. Age-matched healthy controls (n=81) were recruited through local advertisements. Demographic details are provided in Table 1. Written informed consent was obtained from each participant. The project was approved by the Human Ethics Committees of Royal Perth Hospital, University of Western Australia and Curtin University.

CMV DNA and antibody
CMV-reactive IgG was quantitated using a lysate of human foreskin fibroblasts (HFF) infected with strain AD169. Cells were harvested after 7 days, sonicated and stored at -80°C. Uninfected HFF were prepared as a negative control. Parallel microtitre plates were coated at 0.5µg/ml (overnight, 4°C) with CMV lysate, HFF lysate, CMV gB (glycoprotein B) prepared in hamster ovary cells (Chiron Diagnostics; Medfield, MA) and CMV IE-1 (Immediate early 1) prepared in E.coli (Miltenyi Biotech; Cologne, Germany). Plates were then blocked with 5%BSA in PBS and washed. Plasma samples pre-diluted in 2%BSA in PBS were run alongside standard plasma from a CMV-seropositive healthy donor and assigned a value of 1000 arbitrary units (AU/ml) for each antigen. Plates were washed after 2hrs and horse-radish peroxide conjugated anti-human IgG (Sigma-Aldrich; St Louis, MI) diluted 1:4000 in 2%BSA in PBS was added for 1hr. Tetramethylbenzidine substrate (Sigma-Aldrich) was added, colour development was stopped with 1M H₂SO₄ and plates were read at 450nm. CMV seronegativity was defined using the CMV lysate assay as <3 standard deviations above the mean antibody levels recorded in 11 samples that were seronegative by the ARCHITECT CMV IgG assay (Abbott Diagnostic Systems; Lake Forrest, IL), creating a cut-off of 3623AU/ml. As a few individuals meeting this criterion had antibodies detectable with gB or IE-1, analyses were repeated using cut-offs of 340AU/ml gB and 3500AU/ml IE-1 antibody.

Clinical assessments
To assess cIMT, the common carotid arteries were examined in accordance with guidelines from the American Society of Echocardiography (13). Briefly; the anterolateral, posterolateral and mediolateral planes were acquired using a 12-15 MHz multi-frequency linear array probe attached to a high resolution ultrasound machine (Aspen, Acuson; Mountain View, CA). Subjects lay supine with a slight hyperextension of the neck and a 45° lateral flexion away from the side.
scanned. The vessel was scanned to exclude any carotid plaque. An R-wave triggered optimal recording of the far wall, 1cm proximal to the carotid bulb, was directly encoded and stored as a digital DICOM file for post hoc analysis.

After a 10 to 20-minute rest period, brachial artery diameter response to FMD was assessed using a 12-15 MHz multi-frequency linear array probe attached to a high resolution ultrasound machine, (14). Briefly, subjects lay supine with their arms extended at ~80° from their torso. A rapid inflation/deflation pneumatic cuff was placed around the arm distal to the olecranon process. When an optimal B-mode image was obtained, images were collected using a fixed insonation angle (<60°). Baseline images were recorded for 1 min, before the forearm cuff was inflated to 220mm Hg for 5mins. Recording resumed 30sec prior to cuff deflation, and continued for 5mins post-deflation. FMD is presented as the relative (%) rise from the baseline diameter.

Diameters were analysed with custom-designed edge-detection and wall-tracking software to minimise investigator bias. Briefly; a region of interest is drawn around the B-mode image of the vessel segment, and the edges are detected automatically. Over 200 individual measurements are taken from each frame. For cIMT analysis, the median value is calculated to represent a single “composite cIMT”. Three sets of these composite values from common carotid arteries are used to determine the mean lumen diameter and cIMT. Analyses of the reproducibility gave a CV of 6.7-10.5% for FMD (15) and 3.5% for cIMT (16).

**Statistical analysis**

Statistical analyses were performed using Prism 5 (GraphPad Software, La Jolla, CA) and SAS (Version 9.2, 2008; Cary, NC). Univariate comparisons used non-parametric Mann–Whitney tests and Spearman’s correlations. Multivariate associations between independent variables (transplantation, age and gender) and measures of CMV antibody (lysate, gB, IE-1) as dependent variables were sought with a separate general linear model (GLM) for each outcome. GLM were then developed with %FMD or maximum cIMT as the outcome, to assess the influence of transplantation, gender, age (in quartiles), BMI (in tertiles), systolic and diastolic blood pressures (in quartiles) and CMV antibodies (in quartiles). Categories were created to assess whether the relationship with %FMD approximated linearity. They were amalgamated where there appeared to be a ‘step function’ rather than a linear relationship, or removed if the relationship appeared to be linear. In each case, backward elimination was used to obtain the most parsimonious model. A p-value<0.05 was taken to indicate a statistically significant association, but p<0.10 was noted.
RESULTS AND DISCUSSION

The 82 RTR cases and 81 healthy controls were similar in age and gender (Table 1). RTR had significantly higher levels of antibody reactive with CMV (lysate, \( p<0.0001 \); gB, \( p<0.0001 \); and IE-1, \( p=0.009 \)) than controls. This remained true when the analysis was restricted to CMV seropositive individuals (Table 1). The optimal GLM for CMV lysate (\( R^2=0.19, p<0.001 \)) included age (\( p=0.006 \)) and transplantation (\( p<0.0001 \)) as significantly associated variables. Similar results were obtained with gB antibody (\( R^2=0.16, p<0.0001 \) with age at \( p=0.027 \) and transplantation at \( p<0.0001 \)), but the optimal model for IE-1 antibody (\( R^2=0.12, p<0.001 \)) included transplantation (\( p=0.007 \)), gender (\( p=0.004 \)) and age (\( p=0.025 \)). In univariate analyses, gender affected levels of IE-1 antibodies (Wilcoxon rank sum, \( p=0.013 \)).

When RTR and controls were considered together, levels of CMV-reactive antibodies were inversely related to the %FMD [lysate \( r=-0.27, p=0.0008 \); gB \( r=-0.29, p=0.0003 \); IE-1 \( r=-0.22, p=0.0065 \)] suggesting an association with impaired vascular function. While these negative associations persisted amongst RTR and control participants analysed separately, the correlations were not significantly different from zero (data not shown). This reflected the reduced range of CMV antibody and %FMD levels, and smaller sample sizes. Accordingly amongst individuals who were CMV-seropositive, univariate analyses (Wilcoxon tests) showed that RTR had impaired vascular function when assessed by the diameter of the brachial artery or %FMD (Table 1). CMV seropositivity decreased the %FMD in RTR compared with CMV negative RTR (\( p=0.066 \)), but this effect was not detected in controls.

The optimal GLM (\( R^2=0.317, p<0.0001 \)) included the presence of CMV lysate antibody (\( p=0.068 \)), age \( >55 \) years (\( p=0.013 \)), gender (\( p<0.0001 \)) and transplantation (\( p<0.0001 \)). The outcome was similar using CMV gB antibody (\( R^2=0.317, p<0.0001 \) with \( p=0.065 \) for gB) but there was no link with CMV IE-1 antibody (\( R^2=0.317, p<0.0001 \) with \( p=0.381 \) for IE-1). In all models tested, BMI and blood pressure (systolic or diastolic) showed no significant association with FMD.

Measures of cIMT did not differ between RTR or controls irrespective of CMV status. There was no relationship between the presence of CMV antibodies and maximum cIMT values, with the optimal GLM (\( R^2=0.29, p<0.001 \)) being based entirely on age (\( p<0.0001 \), linear term: mean cIMT increased by 0.074 per decade of life). Plaques were detected in only 11 cases, so Fisher’s Exact tests were used to assess associations with the independent variables. These analyses associated
the presence of plaques with transplantation (Fishers test; p=0.003), but found no link with CMV lysate antibody (p=0.64), IE-1 antibody (p=0.72) or gB antibody (p=0.56).

Overall there was a weak association between CMV seropositivity and the earliest marker of vascular dysfunction (%FMD), but not with cIMT, blood pressure or the presence of plaques. The negative findings may reflect the use of antibodies to mark the burden of CMV disease, the small sample size and/or the assessment of individuals with minimal or no symptoms of CMV replication or cardiovascular disease. The absence of CMV replication may be critical as there are additional mechanisms by which active CMV replication may cause vasculopathy – this includes the induction of arginase II or endothelin receptor type B (17, 18).

CMV antibody levels must be interpreted in the context of a lifetime of chronic exposure. In HIV patients, a higher CMV antibody level may mark a better immune response and consequently lower CMV replication (19). Alternatively, higher CMV antibody titres may suggest repeated reactivations of CMV antigens in individuals with subtle immune deficiencies and chronic immune activation, explaining the high titres seen in patients with advanced HIV disease or chronic obstructive pulmonary disease (20). It is also possible that these conditions (like renal transplantation) potentiate reactivations of CMV. Here CMV antibody levels rose with age and with transplantation, both of which affected FMD so the role of CMV is difficult to discern. We are now evaluating more robust measures of the burden of CMV in the context of vascular biology and transplantation.

AUTHORS CONTRIBUTIONS

PP initiated and supervised the study and prepared the manuscript, SL assessed CMV antibodies, JA recruited study subjects and tabulated the data, RP carried out statistical analyses, LN and GW managed the cardiovascular assessments and AI designed and managed aspects of the work pertaining to renal transplantation.
ACKNOWLEDGEMENTS

The authors thank the renal transplant patients and control subjects who participated in this study, and Ms Anne Wargner, Ms Lisa Rich, Ms Nandini Makwana and Mr Alvin Borce for assistance with the recruitment and clinical assessment. The project was supported by the National Health and Medical Research Council of Australia (Grant 1068652).

REFERENCES


Table 1: Levels of CMV antibody and FMD values are higher in RTR than control subjects.

<table>
<thead>
<tr>
<th></th>
<th>RTR CMV + A</th>
<th>RTR CMV - B</th>
<th>Controls CMV + C</th>
<th>Controls CMV - D</th>
<th>A vs B P</th>
<th>A vs C P</th>
<th>C vs D P</th>
</tr>
</thead>
<tbody>
<tr>
<td>n</td>
<td>69</td>
<td>13</td>
<td>51</td>
<td>30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male:Female</td>
<td>39:30</td>
<td>7:6</td>
<td>21:30</td>
<td>17:13</td>
<td>1.00f</td>
<td>0.14</td>
<td>0.25</td>
</tr>
<tr>
<td>Age (years)</td>
<td>57(31-76)(d)</td>
<td>53(33-62)</td>
<td>55(21-86)</td>
<td>49(31-73)</td>
<td>0.14</td>
<td>0.15</td>
<td>0.47</td>
</tr>
<tr>
<td>BMI</td>
<td>26(17-58)</td>
<td>30(25-40)</td>
<td>26(18-40)</td>
<td>27(19-38)</td>
<td>0.02</td>
<td>0.23</td>
<td>0.53</td>
</tr>
<tr>
<td>CMV lysate(a)</td>
<td>795(56-7611)</td>
<td>0.5(0-3.2)</td>
<td>252(3.8-1496)</td>
<td>0.09(0-2.4)</td>
<td>&lt;0.0001</td>
<td>&lt;0.0001</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>CMV gB(b)</td>
<td>32(2.5-293)</td>
<td>0.007(0-0.3)</td>
<td>11(0.2-40)</td>
<td>0.1(0-2)</td>
<td>&lt;0.0001</td>
<td>&lt;0.0001</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>CMV IE-1(a)</td>
<td>12(0.5-477)</td>
<td>3(1.5-9.2)</td>
<td>9.2(0.9-156)</td>
<td>4.2(1.5-51)</td>
<td>&lt;0.0001</td>
<td>0.055</td>
<td>0.003</td>
</tr>
<tr>
<td>ba(b) at rest mm</td>
<td>4.1(2.6-5.8)</td>
<td>4.5(3.9-5.3)</td>
<td>3.4(2.1-5.1)</td>
<td>3.6(2.6-5.5)</td>
<td>0.59</td>
<td>&lt;0.0001</td>
<td>0.76</td>
</tr>
<tr>
<td>ba inflated (mm)</td>
<td>4.2(2.8-5.9)</td>
<td>4.7(3.2-5.4)</td>
<td>3.7(2.4-5.4)</td>
<td>3.9(2.9-5.8)</td>
<td>0.42</td>
<td>0.001</td>
<td>0.54</td>
</tr>
<tr>
<td>%FMD(c)</td>
<td>3.5(0-16)</td>
<td>5.9(2.3-13)</td>
<td>7.9(1.4-14)</td>
<td>7.8(1.5-18)</td>
<td>0.066</td>
<td>&lt;0.0001</td>
<td>0.43</td>
</tr>
<tr>
<td>seconds to peak</td>
<td>59(19-225)</td>
<td>73(20-174)</td>
<td>53(20-156)</td>
<td>65(33-92)</td>
<td>0.21</td>
<td>0.4</td>
<td>0.10</td>
</tr>
<tr>
<td>Left cIMT</td>
<td>0.66(0.44-1.3)</td>
<td>0.65(0.53-1)</td>
<td>0.65(0.44-0.92)</td>
<td>0.62(0.45-0.87)</td>
<td>0.87</td>
<td>0.49</td>
<td>0.13</td>
</tr>
<tr>
<td>Right cIMT</td>
<td>0.63(0.43-1.3)</td>
<td>0.68(0.57-1)</td>
<td>0.65(0.42-1.2)</td>
<td>0.58(0.46-0.89)</td>
<td>0.25</td>
<td>0.96</td>
<td>0.21</td>
</tr>
<tr>
<td>Plaques (yes:no)</td>
<td>6:56</td>
<td>4:8</td>
<td>1:50</td>
<td>0:30</td>
<td>0.25f</td>
<td>0.13</td>
<td>1.00</td>
</tr>
<tr>
<td>BP - systolic</td>
<td>125(97-189)</td>
<td>121(100-141)</td>
<td>119(90-158)</td>
<td>125(98-178)</td>
<td>0.23</td>
<td>0.055</td>
<td>0.31</td>
</tr>
<tr>
<td>BP - diastolic</td>
<td>72(58-96)</td>
<td>71(60-84)</td>
<td>71(52-91)</td>
<td>71(57-98)</td>
<td>0.93</td>
<td>0.38</td>
<td>0.99</td>
</tr>
</tbody>
</table>

\(a\) antibody assessed in AU/ml divided by 1000

\(b\) diameter of brachial artery (ba)

\(c\) \([(ba \text{ inflated} - ba \text{ at rest})/ba \text{ at rest}] \times 100\)

\(d\) median (range) for all continuous variables

\(e\) Mann Whitney Rank Sum test unless otherwise specified

\(f\) Fisher’s Exact test